2026-10-01T23:27:07Zhttps://riubu.ubu.es/oai/request

oai:riubu.ubu.es:10259/121992026-09-30T00:05:47Zcom_10259_11209com_10259_5086com_10259_2604col_10259_11210

00925njm 22002777a 4500 dc Labrador, Jorge author Saiz Rodríguez, Miriam author de Miguel, Dunia author de Laiglesia, Almudena author Rodríguez Medina, Carlos author Vidriales, María Belén author Pérez Encinas, Manuel author Sánchez Sánchez, María José author Cuello, Rebeca author Roldán Pérez, Alicia author Vives, Susana author Benzo Callejo, Gonzalo author Colorado, Mercedes author García Fortes, María author Sayas, María José author Olivier, Carmen author Recio, Isabel author Conde Royo, Diego author Bienert García, Álvaro author Vahi, María author Muñoz García, Carmen author Seri Merino, Cristina author Tormo, Mar author Vall llovera, Ferran author Foncillas, María Ángeles author Martínez Cuadrón, David author Sanz, Miguel Ángel author Montesinos, Pau author 2022-03 The effectiveness of venetoclax (VEN) in relapsed or refractory acute myeloid leukemia (RR-AML) has not been well established. This retrospective, multicenter, observational database studied the effectiveness of VEN in a cohort of 51 RR-AML patients and evaluated for predictors of response and overall survival (OS). The median age was 68 years, most were at high risk, 61% received ≥2 therapies for AML, 49% had received hypomethylating agents, and ECOG was ≥2 in 52%. Complete remission (CR) rate, including CR with incomplete hematological recovery (CRi), was 12.4%. Additionally, 10.4% experienced partial response (PR). The CR/CRi was higher in combination with azacitidine (AZA; 17.9%) than with decitabine (DEC; 6.7%) and low-dose cytarabine (LDAC; 0%). Mutated NPM1 was associated with increased CR/CRi. Median OS was 104 days (95% CI: 56–151). For the combination with AZA, DEC, and LDAC, median OS was 120 days, 104 days, and 69 days, respectively; p = 0.875. Treatment response and ECOG 0 influenced OS in a multivariate model. A total of 28% of patients required interruption of VEN because of toxicity. Our real-life series describes a marginal probability of CR/CRi and poor OS after VEN-based salvage. Patients included had very poor-risk features and were heavily pretreated. The small percentage of responders did not reach the median OS https://hdl.handle.net/10259/12199 10.3390/CANCERS14071734 2072-6694 Venetoclax Acute myeloid leukemia Relapsed Refractory Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience